- Home
- YI vs SCYX Comparison
YI vs SCYX Comparison
Compare YI & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YI
- SCYX
- Stock Information
- Founded
- YI 2010
- SCYX 1999
- Country
- YI China
- SCYX United States
- Employees
- YI N/A
- SCYX N/A
- Industry
- YI Retail-Drug Stores and Proprietary Stores
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- YI Consumer Staples
- SCYX Health Care
- Exchange
- YI Nasdaq
- SCYX Nasdaq
- Market Cap
- YI 38.1M
- SCYX 32.3M
- IPO Year
- YI N/A
- SCYX 2014
- Fundamental
- Price
- YI $4.34
- SCYX $0.59
- Analyst Decision
- YI
- SCYX Strong Buy
- Analyst Count
- YI 0
- SCYX 1
- Target Price
- YI N/A
- SCYX $3.00
- AVG Volume (30 Days)
- YI 10.3K
- SCYX 583.1K
- Earning Date
- YI 11-26-2025
- SCYX 11-05-2025
- Dividend Yield
- YI N/A
- SCYX N/A
- EPS Growth
- YI N/A
- SCYX N/A
- EPS
- YI N/A
- SCYX N/A
- Revenue
- YI $1,979,883,442.00
- SCYX $3,257,000.00
- Revenue This Year
- YI N/A
- SCYX $368.39
- Revenue Next Year
- YI N/A
- SCYX $123.36
- P/E Ratio
- YI N/A
- SCYX N/A
- Revenue Growth
- YI N/A
- SCYX N/A
- 52 Week Low
- YI $4.15
- SCYX $0.62
- 52 Week High
- YI $11.35
- SCYX $1.49
- Technical
- Relative Strength Index (RSI)
- YI 37.45
- SCYX 23.53
- Support Level
- YI $4.20
- SCYX $0.68
- Resistance Level
- YI $4.43
- SCYX $0.82
- Average True Range (ATR)
- YI 0.16
- SCYX 0.04
- MACD
- YI 0.05
- SCYX -0.01
- Stochastic Oscillator
- YI 23.28
- SCYX 1.63
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.